The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 20, 2018
Filed:
Apr. 02, 2014
N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
Applicant:
Janssen Sciences Ireland Uc, Little Island, Co Cork, IE;
Inventors:
Koen Vandyck, Paal-Beringen, BE;
Geerwin Yvonne Paul Haché, Kapellen, BE;
Stefaan Julien Last, Lint, BE;
Pierre Jean-Marie Bernard Raboisson, Rosieres, BE;
Assignee:
Janssen Sciences Ireland US, Little Island, County Cork, IE;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 487/08 (2006.01); C07D 207/16 (2006.01); C07D 209/42 (2006.01); A61K 31/4025 (2006.01); A61K 31/403 (2006.01); A61K 31/404 (2006.01); A61K 31/407 (2006.01); A61K 45/06 (2006.01); C07D 207/48 (2006.01); C07D 209/52 (2006.01); C07D 403/12 (2006.01); C07D 487/04 (2006.01); C07D 491/107 (2006.01);
U.S. Cl.
CPC ...
A61K 31/40 (2013.01); A61K 31/403 (2013.01); A61K 31/404 (2013.01); A61K 31/407 (2013.01); A61K 31/4025 (2013.01); A61K 45/06 (2013.01); C07D 207/16 (2013.01); C07D 207/48 (2013.01); C07D 209/42 (2013.01); C07D 209/52 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 491/107 (2013.01);
Abstract
Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R, R, Rand Rhave the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.